Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)

被引：0

作者：

Lorenza, Rimassa ^{[1
]}

Silvia, Bozzarelli ^{[1
]}

Stefano, Cordio ^{[2
]}

Filippo, Pietrantonio ^{[3
]}

Laura, Toppo ^{[4
]}

Sara, Lonardi ^{[5
]}

Alberto, Zaniboni ^{[6
]}

Roberto, Bordonaro ^{[7
]}

Maria, Di Bartolomeo ^{[8
]}

Wanda, Liguigli ^{[4
]}

Vittorina, Zagonel ^{[5
]}

Chiara, Tronconi Maria ^{[1
]}

Luca, Di Tommaso ^{[9
]}

Laura, Giordano ^{[1
]}

Armando, Santoro ^{[1
]}

机构：

[1] Ist Clin Humanitas IRCCS, Humanitas Canc Ctr, Rozzano, Italy

[2] Garibaldi Nesima Hosp, Dept Oncol, Catania, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[4] Ist Ospitalieri Cremona, Struttura Complessa Oncol, Cremona, Italy

[5] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy

[6] Fdn Poliambulanza, Brescia, Italy

[7] Osped Garibaldi, Unita Oncol Med, Catania, Italy

[8] Fdn IRCCS Ist Nazl Tumori, Dept Oncol, Milan, Italy

[9] Ist Clin Humanitas IRCCS, Dept Pathol, Rozzano, Italy

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD - 028

引用

页数：1

共 50 条

[41] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer [J].

I. Garrido-Laguna ;

K. A. McGregor ;

M. Wade ;

J. Weis ;

W. Gilcrease ;

L. Burr ;

R. Soldi ;

L. Jakubowski ;

C. Davidson ;

G. Morrell ;

J. D. Olpin ;

K. Boucher ;

D. Jones ;

S. Sharma .

Investigational New Drugs, 2013, 31 :1257-1264

[42] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer [J].

Baker, J. B. ;

Dutta, D. ;

Watson, D. ;

Maddala, T. ;

Munneke, B. M. ;

Shak, S. ;

Rowinsky, E. K. ;

Xu, L-A ;

Harbison, C. T. ;

Clark, E. A. ;

Mauro, D. J. ;

Khambata-Ford, S. .

BRITISH JOURNAL OF CANCER, 2011, 104 (03) :488-495

[43] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer [J].

J B Baker ;

D Dutta ;

D Watson ;

T Maddala ;

B M Munneke ;

S Shak ;

E K Rowinsky ;

L-A Xu ;

C T Harbison ;

E A Clark ;

D J Mauro ;

S Khambata-Ford .

British Journal of Cancer, 2011, 104 :488-495

[44] Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer [J].

Pander, Jan ;

Gelderblom, Hans ;

Antonini, Ninja F. ;

Tol, Jolien ;

van Krieken, Johan H. J. M. ;

van der Straaten, Tahar ;

Punt, Cornelis J. A. ;

Guchelaar, Henk-Jan .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) :1829-1834

[45] EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy [J].

Uhlyarik, Andrea ;

Piurko, Violetta ;

Papai, Zsuzsanna ;

Raso, Erzsebet ;

Lahm, Erika ;

Kiss, Edina ;

Sikter, Marta ;

Vachaja, Jozsef ;

Kenessey, Istvan ;

Timar, Jozsef .

CANCERS, 2020, 12 (03)

[46] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [J].

Yuki, S. ;

Shitara, K. ;

Yoshida, M. ;

Takahari, D. ;

Utsunomiya, S. ;

Yokota, T. ;

Sato, Y. ;

Tajika, M. ;

Muro, K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)

[47] RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer RESPONSE [J].

Sclafani, Francesco ;

Cunningham, David ;

Peckitt, Clare ;

Watkins, David .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (03)

[48] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [J].

Kohei Shitara ;

Satoshi Yuki ;

Motoki Yoshida ;

Daisuke Takahari ;

Setsuo Utsunomiya ;

Tomoya Yokota ;

Yozo Sato ;

Yoshitaka Inaba ;

Masahiro Tajika ;

Hiroki Kawai ;

Hidekazu Yamaura ;

Mina Kato ;

Kentaro Yamazaki ;

Yoshito Komatsu ;

Kei Muro .

Investigational New Drugs, 2012, 30 :787-793

[49] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [J].

Shitara, Kohei ;

Yuki, Satoshi ;

Yoshida, Motoki ;

Takahari, Daisuke ;

Utsunomiya, Setsuo ;

Yokota, Tomoya ;

Sato, Yozo ;

Inaba, Yoshitaka ;

Tajika, Masahiro ;

Kawai, Hiroki ;

Yamaura, Hidekazu ;

Kato, Mina ;

Yamazaki, Kentaro ;

Komatsu, Yoshito ;

Muro, Kei .

INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) :787-793

[50] Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies [J].

Kohne, C. ;

Bokemeyer, C. ;

Heeger, S. ;

Sartorius, U. ;

Rougier, P. ;

Van Cutsem, E. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →